Risk factors associated with development of coinfection in critically Ill patients with COVID-19
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: At outset of the coronavirus disease 2019 (COVID-19) pandemic, the significance of bacterial and fungal coinfections in individuals with COVID-19 was unknown. Initial reports indicated that the prevalence of coinfection in the general population was low, but there was uncertainty regarding the risk of coinfection in critically ill patients.Methods: Nine hundred critically ill adult patients with COVID-19 infection were enrolled in this observational case-control study. Patients with a coinfection (case) and patients without a coinfection (control) were compared using univariate and multivariable analyses. A subgroup analysis was performed on patients with coinfection, dividing them into early (infection within 7 days) and late (infection after 7 days) infection groups.Results: Two hundred and thirty-three patients (25.9%) had a bacterial or fungal coinfection. Vasopressor use (P<0.001) and severity of illness (higher Acute Physiology and Chronic Health Evaluation III score, P=0.009) were risk factors for the development of a coinfection. Patients with coinfection had higher mortality and length of stay. Vasopressor and corticosteroid use and central line and foley catheter placement were risk factors for late infection (>7 days). There were high rates of drug-resistant infections.Conclusions: Critically ill patients with COVID-19 are at risk for both community-acquired and hospital-acquired infections throughout their hospitalization for COVID-19. It is important to consider the development of a coinfection in clinically worsening critically ill patients with COVID-19 and consider the likelihood of drug-resistance when choosing an empiric regimen.
Abstract
Background: At outset of the coronavirus disease 2019 (COVID-19) pandemic, the significance of bacterial and fungal coinfections in individuals with COVID-19 was unknown. Initial reports indicated that the prevalence of coinfection in the general population was low, but there was uncertainty regarding the risk of coinfection in critically ill patients.Methods: Nine hundred critically ill adult patients with COVID-19 infection were enrolled in this observational case-control study. Patients with a coinfection (case) and patients without a coinfection (control) were compared using univariate and multivariable analyses. A subgroup analysis was performed on patients with coinfection, dividing them into early (infection within 7 days) and late (infection after 7 days) infection groups.Results: Two hundred and thirty-three patients (25.9%) had a bacterial or fungal coinfection. Vasopressor use (P<0.001) and severity of illness (higher Acute Physiology and Chronic Health Evaluation III score, P=0.009) were risk factors for the development of a coinfection. Patients with coinfection had higher mortality and length of stay. Vasopressor and corticosteroid use and central line and foley catheter placement were risk factors for late infection (>7 days). There were high rates of drug-resistant infections.Conclusions: Critically ill patients with COVID-19 are at risk for both community-acquired and hospital-acquired infections throughout their hospitalization for COVID-19. It is important to consider the development of a coinfection in clinically worsening critically ill patients with COVID-19 and consider the likelihood of drug-resistance when choosing an empiric regimen.
참고문헌 (34)
- "COVID-19 Map: Johns Hopkins coronavirus resource center" (2021)[URL]
- Metersky ML, "Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza", Int J Infect Dis, 16, pp.e321~e331 (2012)
- Bakaletz LO, "Viral-bacterial co-infections in the respiratory tract", Curr Opin Microbiol, 35, pp.30~35 (2017)
- Hughes S, "Bacterial and fungal coinfection among hospitalized patients with COVID-19 : a retrospective cohort study in a UK secondary-care setting", Clin Microbiol Infect, 26, pp.1395~1399 (2020)
- Garcia-Vidal C, "Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study", Clin Microbiol Infect, 27, pp.83~88 (2021)
- Karaba SM, "Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study", Open Forum Infect Dis, 8, pp.ofaa578~ (2020)
- Youngs J, "Improving antibiotic stewardship in COVID-19 : bacterial co-infection is less common than with influenza", J Infect, 81, pp.e55~e57 (2020)
- Sepulveda J, "Bacteremia and blood culture utilization during COVID-19 surge in New York City", J Clin Microbiol, 58, pp.e00875-20~ (2020)
- Rawson TM, "Bacterial and fungal coinfection in individuals with coronavirus : a rapid review to support COVID-19 antimicrobial prescribing", Clin Infect Dis, 71, pp.2459~2468 (2020)
- Bhatt PJ, "Risk factors and outcomes of hospitalized patients with severe coronavirus disease 2019 (COVID-19) and secondary bloodstream infections: a multicenter case-control study", Clin Infect Dis, 72, pp.e995~e1003 (2019)
- Sharifipour E, "Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU", BMC Infect Dis, 20, pp.646~ (2020)
- Zhang H, "Risks and features of secondary infections in severe and critical ill COVID-19 patients", Emerg Microbes Infect, 9, pp.1958~1964 (2020)
- Baskaran V, "Co-infection in critically ill patients with COVID-19 : an observational cohort study from England", J Med Microbiol, 70, pp.001350~ (2021)
- d’Humières C, "Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France", PLoS One, 16, pp.e0250728~ (2021)
- Lansbury L, "Co-infections in people with COVID-19 : a systematic review and meta-analysis", J Infect, 81, pp.266~275 (2020)
- Langford BJ, "Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis", Clin Microbiol Infect, 26, pp.1622~1629 (2020)
- Chang CY, "Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics", J Infect, 81, pp.e29~e30 (2020)
- Han J, "Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19", Clin Med(Lond), 20, pp.e47~ (2020)
- Vanhomwegen C, "Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit", Ir J Med Sci, 190, pp.1649~1652 (2021)
- Loke HY, "Length of stay and odds of MRSA acquisition : a dose-response relationship", Epidemiol Infect, 147, pp.e223~ (2019)
- Tess BH, "Incidence of hospital-acquired infection and length of hospital stay", Eur J Clin Microbiol Infect Dis, 12, pp.81~86 (1993)
- Stekhoven DJ, "MissForest : non-parametric missing value imputation for mixed-type data", Bioinformatics, 28, pp.112~118 (2012)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Cleveland Clinic Foundation, "Cumulative antimicrobial susceptibility of bacteria from cultures at CCF main campus", Cleveland Clinic Intranet, ~
- Nasir N, "Risk factors for bacterial infections in patients with moderate to severe COVID-19 : a case-control study", J Med Virol, 93, pp.4564~4569 (2021)
- Klein EY, "The frequency of influenza and bacterial coinfection : a systematic review and meta-analysis", Influenza Other Respir Viruses, 10, pp.394~403 (2016)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with COVID-19", N Engl J Med, 384, pp.693~704 (2021)
- George MD, "Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis : a cohort study", Ann Intern Med, 173, pp.870~878 (2020)
- Obata R, "Increased secondary infection in COVID-19 patients treated with steroids in New York City", Jpn J Infect Dis, 74, pp.307~315 (2021)
- Bassetti M, "Bacterial and fungal superinfections in critically ill patients with COVID-19", Intensive Care Med, 46, pp.2071~2074 (2020)
- Grasselli G, "Critical care utilization for the COVID-19 outbreak in Lombardy, Italy : early experience and forecast during an emergency response", JAMA, 323, pp.1545~1546 (2020)
- Heesom L, "Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit", J Glob Antimicrob Resist, 22, pp.782~784 (2020)
- Lippi G, "Procalcitonin in patients with severe coronavirus disease 2019(COVID-19) : a meta-analysis", Clin Chim Acta, 505, pp.190~191 (2020)
- Huang I, "C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019 : a meta-analysis", Ther Adv Respir Dis, 14, pp.1753466620937175~ (2020)